Avalanche Biotechnologies, Inc. Securities Litigation
On or around 02/05/2018 (Court's order of dismissal)
Filing Date: July 09, 2015
According to the law firm press release, the lawsuit alleges Defendants made materially false and/or misleading statements and failed to disclose that Phase 2a of the AVA-101 study was not designed to show any statistical significance between the active and control groups in the secondary endpoints. When the true details entered the market, the lawsuit claims that investors suffered damages.
On December 17, 2015, the Court appointed lead plaintiff and approved the selection of lead counsel. Lead plaintiff filed the consolidated complaint on January 29, 2016.
On November 3, 2016, the Court issued an Order granting Defendants' Motions to Dismiss. Plaintiffs were given leave to file an amended complaint. An amended complaint was filed on December 2, 2016.
On August 21, 2017, the Court issued an Order staying the case pending settlement of the state action. On February 5, 2018, the Court issued an Order dismissing the case with prejudice, as a final settlement encompassing the putative class and claims in this case was approved in another Court.
Company & Securities Information
Defendant: Avalanche Biotechnologies, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AAVL
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Joe Huang, et al. v. Avalanche Biotechnologies, Inc., et al.